((1S,2S,4S)-2-hydroxy-4-hydroxymethyl-1-((S)-2-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-3-methyl-butyl)-5-methyl-hexyl)-carbamic acid tert-butyl ester | 866030-34-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ((1S,2S,4S)-2-hydroxy-4-hydroxymethyl-1-((S)-2-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-3-methyl-butyl)-5-methyl-hexyl)-carbamic acid tert-butyl ester
• 英文别名: ((1S,2S,4S)-2-hydroxy-4-hydroxymethyl-1{(S)-2-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-3-methyl-butyl}-5-methyl-hexyl)-carbamic acid tert-butyl ester；((1S,2S,4S)-2-Hydroxy-4-hydroxymethyl-1-{(S)-2-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-3-methyl-butyl}-5-methyl-hexyl)-carbamic acid tert-butyl ester；tert-butyl N-[(3S,5S,6S,8S)-6-hydroxy-8-(hydroxymethyl)-3-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-2,9-dimethyldecan-5-yl]carbamate
• CAS: 866030-34-4
• 化学式: C₃₀H₅₃NO₇
• 分子量: 539.753
• InChiKey: KLMZYOAWNAEHPR-QYOOZWMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  38
• 可旋转键数：
  19
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  ((1S,2S,4S)-2-hydroxy-4-hydroxymethyl-1-((S)-2-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-3-methyl-butyl)-5-methyl-hexyl)-carbamic acid tert-butyl ester 在 2-羟基吡啶 、 三甲基氯硅烷 、 四丙基高钌酸铵 、 N-甲基吗啉氧化物 、 三乙胺 、 苯酚 作用下， 以 二氯甲烷 为溶剂， 生成 阿利克仑
  参考文献：
  名称：

  Practical synthesis of an orally active renin inhibitor aliskiren

  摘要：

  A convergent synthesis of aliskiren was accomplished via the use of Segment AB as the key intermediate, which was prepared via the coupling of the Grignard reagent derived from Segment B with Segment A, followed by subsequent oxidative lactonization. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2005.07.028
• 作为产物：
  描述：

  (4R)-3-[(2S)-3-甲基-1-氧代-2-[(苄氧基)甲基]丁基]-4-苄基-2-恶唑啉酮 在 palladium dihydroxide lithium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 lithium aluminium tetrahydride 、 氢气 、 双氧水 、 magnesium 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 ((1S,2S,4S)-2-hydroxy-4-hydroxymethyl-1-((S)-2-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-3-methyl-butyl)-5-methyl-hexyl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Practical synthesis of an orally active renin inhibitor aliskiren

  摘要：

  A convergent synthesis of aliskiren was accomplished via the use of Segment AB as the key intermediate, which was prepared via the coupling of the Grignard reagent derived from Segment B with Segment A, followed by subsequent oxidative lactonization. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2005.07.028

文献信息

• ORGANIC COMPOUNDS
  申请人：Mickel Stuart John

  公开号：US20100274027A1

  公开（公告）日：2010-10-28

  The invention provides a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Allskiren. Inter alia, the invention provides a process for the manufacture of a compound of the formula III, wherein R, R 1 , R 2 , R 3 and PG are as defined in the specification, or a salt thereof. The manufacture comprises (preferably consists of) reacting a compound of the formula I, with a reagent able to transform hydroxy into X where X is for example a leaving group.

  本发明提供了一种新的过程、新的过程步骤和新的中间体，用于合成药物活性化合物，特别是肾素抑制剂，例如Allskiren。此外，本发明还提供了一种制备式III化合物或其盐的方法，其中R、R1、R2、R3和PG如规范中所定义。该制备方法包括（最好是由）将式I化合物与能够将羟基转化为X的试剂反应，其中X例如是一个离去基团。
• Organic Compounds
  申请人：Mickel Stuart John

  公开号：US20080207921A1

  公开（公告）日：2008-08-28

  The invention related to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren. Inter alia, the invention relates to a process for the manufacture of a compound of the formula III, wherein R, R 1 , R 2 , R 3 and PG are as defined in the specification, or a salt thereof, said manufacture comprising (preferably consisting in) reacting a compound of the formula I,

  本发明涉及一种新颖的过程、新颖的过程步骤和新颖的中间体，用于合成药物活性化合物，特别是肾素抑制剂，如阿利司他。此外，本发明涉及一种制备式III化合物的过程，其中R、R1、R2、R3和PG如规范中所定义，或其盐，所述制备包括（最好是由）反应式I化合物。
• Synthesis of Renin Inhibitors Involving a Cycloaddition Reaction
  申请人：Mickel Stuart John

  公开号：US20080255369A1

  公开（公告）日：2008-10-16

  The invention related to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren. Inter alia, the invention relates to a process for the manufacture of a compound of the formula III, wherein R, R 1 , and R′ are as defined in the specification, or a salt thereof, and a compound of formula IV wherein R, R 1 , R 2 and R′ are as defined in the specification, and processes of manufacturing these.

  该发明涉及一种新颖的工艺、新颖的工艺步骤和新颖的中间体，可用于合成药物活性化合物，特别是肾素抑制剂，例如阿利司他。此外，该发明涉及一种制备式III化合物的工艺，其中R、R1和R′如规范中定义，或其盐，以及式IV化合物的工艺，其中R、R1、R2和R′如规范中定义，并制备这些化合物的工艺。
• Process for preparing renin inhibitors
  申请人：Novartis AG

  公开号：US07767831B2

  公开（公告）日：2010-08-03

  The present invention provides a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren. Inter alia, the invention provides a process for the manufacture of a compound of the formula III, wherein R, R1, R2, R3 and PG are as defined in the specification, or a salt thereof. The manufacture comprises (preferably consists of) reacting a compound of the formula I, with a reagent able to transform hydroxy into X where X is for example a leaving group.

  本发明提供了一种新颖的过程、新颖的过程步骤和新颖的中间体，可用于合成药物活性化合物，特别是肾素抑制剂，如阿利司他。此外，本发明提供了一种用于制造公式III化合物或其盐的方法，其中R、R1、R2、R3和PG如规范中所定义。制造包括（最好仅包括）将公式I化合物与能将羟基转化为X的试剂反应，其中X例如是一个离去基团。
• SYNTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION
  申请人：Mickel Stuart John

  公开号：US20110230665A1

  公开（公告）日：2011-09-22

  The invention related to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren. Inter alia, the invention relates to a process for the manufacture of a compound of the formula III, wherein R, R 1 , and R′ are as defined in the specification, or a salt thereof, and a compound of formula IV wherein R, R 1 , R 2 and R′ are as defined in the specification, and processes of manufacturing these.

  这项发明涉及一种新颖的过程、新颖的过程步骤和新颖的中间体，可用于合成药物活性化合物，特别是肾素抑制剂，如阿利司他。此外，该发明涉及一种用于制造公式III化合物的过程，其中R、R1和R′如规范中所定义，或其盐，以及公式IV化合物的过程，其中R、R1、R2和R′如规范中所定义，并制造这些化合物的过程。